Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd (VENMAX) last reported results for the quarter ended Jun 2026, with sales of ₹2.48 crore and net profit of ₹0.12 crore. The next scheduled event is a merger acquisition on 24 Oct 2026. The stock last traded at ₹15, a market capitalisation of ₹21.7 crore, on a P/E of 77.5. Over the past 52 weeks the stock has ranged between ₹12.7 and ₹31.5. Figures are as of 6 Oct 2026 and are not real time.
Venmax Drugs and Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹15
- Market cap
- ₹21.7 cr
- Stock P/E
- 77.5
- Book value
- ₹13
- ROE
- 2.70%
- ROCE
- 2.96%
- Dividend yield
- 0.00%
- 52w high / low
- 31.5/12.7
Metrics as of 6 Oct 2026. Not real time.
Track Venmax Drugs and Pharmaceuticals Ltd
Cruxal reads every Venmax Drugs and Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Venmax Drugs and Pharmaceuticals Ltd growth and returns
- 10 Years
- 15%
- 5 Years
- 116%
- 3 Years
- %
- TTM
- 386%
- 10 Years
- 14%
- 5 Years
- 29%
- 3 Years
- 3%
- TTM
- 1300%
- 10 Years
- 20%
- 5 Years
- %
- 3 Years
- %
- 1 Year
- -25%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 3%
Venmax Drugs and Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2.48 cr, up 105.0% from ₹1.21 cr a year earlier. Net profit was ₹0.12 cr, up 200.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.17 | 0.2 | 0.33 | 1.21 | 1.32 | 1.55 | 3.94 | 2.48 |
| Expenses | 0.47 | 0.69 | 0.57 | 1.17 | 1.27 | 1.58 | 3.92 | 2.36 |
| Operating profit | -0.3 | -0.49 | -0.24 | 0.04 | 0.05 | -0.03 | 0.02 | 0.12 |
| OPM % | -176.47% | -245.00% | -72.73% | 3.31% | 3.79% | -1.94% | 0.51% | 4.84% |
| Other income | 0 | 0 | 1.02 | 0 | 0 | 0.07 | 0.09 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0.3 | -0.49 | 0.78 | 0.04 | 0.05 | 0.04 | 0.11 | 0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 40.00% | 25.00% | 0.00% | 0.00% |
| Net profit | -0.3 | -0.5 | 0.78 | 0.04 | 0.02 | 0.03 | 0.11 | 0.12 |
| EPS (₹) | -0.57 | -0.95 | 1.49 | 0.08 | 0.02 | 0.04 | 0.09 | 0.10 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Venmax Drugs and Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.26 | 0 | 0.15 | 0.47 | 0.17 | 0 | 0 | 0 | 0.81 | 8.02 | 9.29 |
| Operating profit | -0.62 | -0.23 | -0.23 | -0.25 | -0.33 | -0.12 | -0.19 | -0.11 | -1.06 | 0.12 | 0.16 |
| OPM % | -238.46% | — | -153.33% | -53.19% | -194.12% | — | — | — | -130.86% | 1.50% | 1.72% |
| Net profit | -1.34 | -0.24 | -0.24 | -0.27 | -0.16 | 1.85 | 0.23 | 0.06 | -0.01 | 0.25 | 0.28 |
| EPS (₹) | -2.56 | -0.46 | -0.46 | -0.52 | -0.31 | 3.53 | 0.44 | 0.11 | -0.02 | 0.22 | 0.25 |
TTM is the trailing twelve months to the most recent quarter.
Venmax Drugs and Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 5.24 | 11.58 |
| Reserves | -7.11 | -7.35 | -7.59 | -7.86 | -8.03 | -6.18 | -5.95 | -5.89 | -0.83 | 2.53 |
| Borrowings | 1.85 | 2.04 | 2.24 | 2.52 | 2.33 | 0.35 | 0.35 | 0.35 | 0.05 | 0.33 |
| Other liabilities | 0.16 | 0.14 | 0.44 | 0.56 | 0.76 | 0.80 | 0.57 | 0.38 | 0.71 | 1.76 |
| Total liabilities | 0.14 | 0.07 | 0.33 | 0.46 | 0.30 | 0.21 | 0.21 | 0.08 | 5.17 | 16.20 |
| Fixed assets | 0.00 | 0.00 | 0.11 | 0.10 | 0.09 | 0.08 | 0.07 | 0.07 | 0.04 | 0.04 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 0.14 | 0.07 | 0.22 | 0.36 | 0.21 | 0.13 | 0.14 | 0.01 | 5.13 | 16.16 |
| Total assets | 0.14 | 0.07 | 0.33 | 0.46 | 0.30 | 0.21 | 0.21 | 0.08 | 5.17 | 16.20 |
As reported by the company. Total assets equal total liabilities by construction.
Venmax Drugs and Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.06 | -0.26 | -0.05 | -0.28 | 0.26 | 1.91 | 0.00 | 0.00 | -2.29 | -11.00 |
| Cash from investing | 0.01 | 0.00 | -0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from financing | 1.02 | 0.26 | 0.16 | 0.28 | -0.19 | -1.98 | 0.00 | 0.00 | 4.77 | 9.74 |
| Net cash flow | -0.03 | 0.00 | 0.00 | 0.00 | 0.07 | -0.07 | 0.00 | 0.00 | 2.48 | -1.26 |
| Free cash flow | -1.05 | -0.26 | -0.17 | -0.28 | 0.26 | 1.91 | 0.00 | 0.00 | -2.29 | -11.00 |
| CFO / operating profit | 171% | 113% | 22% | 112% | -79% | -1,592% | 0% | -18% | 216% | -9,142% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Venmax Drugs and Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| ROCE % | -52.63% | — | — | — | -0.96% | 2.96% |
| Debtor days | 0.00 | 0.00 | 31.06 | 85.88 | 428.09 | 65.08 |
| Inventory days | 0.00 | 446.11 | 250.94 | 0.00 | 27.72 | 50.14 |
| Days payable | — | 1,257.22 | 456.25 | — | 291.08 | 84.23 |
| Cash conversion cycle | 0.00 | -811.11 | -174.25 | 85.88 | 164.73 | 30.99 |
| Working capital days | -2,723.46 | -5,986.00 | -2,112.34 | -6,333.82 | 874.20 | 587.55 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Venmax Drugs and Pharmaceuticals Ltd shareholding pattern
Promoters held 10.46% at Jun 2026, down from 23.13% at Jun 2025. DIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 23.13% | 23.13% | 23.13% | 23.13% | 23.13% | 15.14% | 13.80% | 10.46% |
| DIIs | 0.15% | 0.15% | 0.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 76.72% | 76.72% | 76.71% | 76.87% | 76.86% | 84.86% | 86.21% | 89.53% |
| No. of shareholders | 6,291 | 6,657 | 6,756 | 6,729 | 6,764 | 6,815 | 6,802 | 6,865 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Venmax Drugs and Pharmaceuticals Ltd events
The next scheduled event is a merger acquisition on 24 Oct 2026.
- Merger acquisitionNCLT convened meeting of equity shareholders for approval of amalgamation scheme
- EGMMeeting of equity shareholders to consider the Composite Scheme of Amalgamation of Hatri Pharma Private Limited with Venmax Drugs and Pharmaceuticals Limited
See the full results calendar for every Indian company reporting in the next 30 days.
Venmax Drugs and Pharmaceuticals Ltd corporate filings
- Certificate under Regulation 74(5) of the SEBI(Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.Company Updatelow impact
- Venmax Drugs and Pharmaceuticals Limited concludes 37th AGM with board restructuring and financial statement adoptionAGM/EGMlow impact
Cruxal's analysis: Venmax Drugs and Pharmaceuticals Limited has successfully concluded its 37th Annual…
Read the full analysis - Venmax Drugs and Pharmaceuticals Announces Proposed Merger with Hatri Pharma Private LimitedAGM/EGMhigh impact
Cruxal's analysis: Venmax Drugs and Pharmaceuticals Limited has formally announced a proposed merger with…
Read the full analysis - Intimation of Closure of Trading Window pursuant to declaration of Unaudited Financial Results for the quarter ended September 30, 2026.Insider Trading / SASTlow impact
- Venmax Drugs and Pharmaceuticals Ltd announces NCLT-convened meeting of equity shareholdersCompany Updatelow impact
Cruxal's analysis: Venmax Drugs and Pharmaceuticals Ltd has published a newspaper advertisement regarding a…
Read the full analysis - Venmax Drugs and Pharmaceuticals Limited Announces NCLT-Convened Meeting for Amalgamation with Hatri Pharma Private LimitedAGM/EGMhigh impact
Cruxal's analysis: Venmax Drugs and Pharmaceuticals Limited has announced a meeting of its equity…
Read the full analysis - Venmax Drugs and Pharmaceuticals Limited Receives NCLT Order to Convene Shareholder Meeting for Amalgamation with Hatri Pharma Private LimitedCompany Updatemedium impact
Cruxal's analysis: Venmax Drugs and Pharmaceuticals Limited has received an NCLT order dated September 7…
Read the full analysis - Venmax Drugs and Pharmaceuticals Ltd submits Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Venmax Drugs and Pharmaceuticals Ltd has filed its Annual Report for the financial year…
Read the full analysis - Venmax Drugs & Pharmaceuticals Announces 37th AGM and Key Board ReconstitutionsBoard Meetinglow impact
Cruxal's analysis: Venmax Drugs & Pharmaceuticals Limited has scheduled its 37th Annual General Meeting for…
Read the full analysis - Venmax Drugs & Pharmaceuticals Limited schedules Board Meeting for August 31, 2026, to approve 37th Annual Report and AGM logisticsBoard Meetinglow impact
Cruxal's analysis: Venmax Drugs & Pharmaceuticals Limited has issued a routine regulatory intimation…
Read the full analysis - Venmax Drugs & Pharmaceuticals Limited Reports Financial Results for Quarter Ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Venmax Drugs & Pharmaceuticals Limited has released its unaudited financial results for…
Read the full analysis - Venmax Drugs and Pharmaceuticals Ltd files Statement of Deviation or Variation for Q1 FY2027Company Updatelow impact
Cruxal's analysis: Venmax Drugs and Pharmaceuticals Ltd has submitted its Statement of Deviation or…
Read the full analysis - Venmax Drugs Reports Q1 FY27 Results and Announces Forfeiture of 7.80 Lakh Partly Paid-up WarrantsBoard Meetingmedium impact
Cruxal's analysis: Venmax Drugs and Pharmaceuticals Limited reported Q1 FY27 revenue from operations of 2.48…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.